P.C

CHILDREN’S PLACE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against The Children’s Place and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, March 4, 2024

Investors have until April 29, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 29, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
  • Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against iRhythm, Hut 8, Xponential, and Amplitude and Encourages Investors to Contact the Firm

Retrieved on: 
Sunday, March 3, 2024

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.

Key Points: 
  • The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
  • The Zio XT is intended for non-critical patients, as it does not provide real-time reporting.
  • These types of heart monitors that are approved for high-risk patients and provide near real-time alerts are also referred to as “real-time” monitors.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

SNOWFLAKE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Snowflake Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 2, 2024

Investors have until April 29, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 29, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • Snowflake is a cloud data platform that enables its enterprise customers to consolidate data into a single source to build data-driven applications and share data.
  • which lowered credit consumption.”  On this news, the price of Snowflake Class A common stock fell nearly 28% over several trading sessions, damaging investors.

MAISON SOLUTIONS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Maison Solutions Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 2, 2024

Investors have until March 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • On May 22, 2023, Maison Solutions filed a registration statement on Form S-1, which after six amendments (and three post-effective amendments) was declared effective on September 29, 2023.
  • On October 5, 2023, Maison Solutions filed a prospectus on Form 424B4 with the SEC in connection with the IPO, which incorporated and formed part of the Registration Statement (the “Prospectus” and, together with the Registration Statement, the “Offering Documents”).

ASSERTIO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Assertio Holdings, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 2, 2024

Investors have until March 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against B. Riley, Evolution, NYCB, and LuxUrban and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 2, 2024

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • For more information on the B. Riley class action go to: https://bespc.com/cases/RILY
    According to the complaint, On January 24, 2022, Analyst Alpha Generation Limited released a report on Evolution (the “Report”) to certain institutional investors.
  • On this news, Evolution's ADS price fell $12.34 per ADS, or 10.88%, to close at $101.09 per ADS on May 5, 2022.
  • For more information on the LuxUrban class action go to: https://bespc.com/cases/LUXH

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 2, 2024

According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Key Points: 
  • According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
  • As a result, ADM delayed its Q4 and FY 2023 earnings release and withdrew its outlook for the Nutrition segment.
  • For more information on the ADM class action go to: https://bespc.com/cases/ADM

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against InMode, Lantronix, and Palo Alto Networks and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 2, 2024

InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.

Key Points: 
  • InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.
  • Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
  • On this news, the price of Palo Alto Networks, Inc. common stock declined by $104.12 per share, or approximately 28%, on February 21, 2024.
  • For more information on the Palo Alto Networks class action go to: https://bespc.com/cases/PANW

NEXTDOOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 1, 2024

Investors have until April 29, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 29, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Nextdoor operates a hyperlocal online social networking platform that connects neighbors, public agencies, and businesses via the internet.
  • On this news, the price of Nextdoor Class A common stock declined approximately 14%.
  • On this news, the price of Nextdoor Class A common stock fell approximately 11%, further damaging investors.

INARI MEDICAL ALERT: Bragar Eagel & Squire, P.C. is Investigating Inari Medical, Inc. on Behalf of Inari Medical Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 1, 2024

NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Inari Medical, Inc. (“Inari Medical” or the “Company”) (NASDAQ: NARI) on behalf of Inari Medical stockholders.

Key Points: 
  • NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Inari Medical, Inc. (“Inari Medical” or the “Company”) (NASDAQ: NARI) on behalf of Inari Medical stockholders.
  • Our investigation concerns whether Inari Medical has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Click here to participate in the action.
  • The CID requests information and documents primarily relating to meals and consulting service payments provided to health care professionals (“HCPs”).